Kiora Pharmaceuticals Enters Securities Purchase Agreement to Sell Common Stock and Warrants
Kiora Pharmaceuticals has entered into a Securities Purchase Agreement with investors to sell shares of common stock, pre-funded warrants, and Tranche A-1 and A-2 common warrants. The agreement also includes a Registration Rights Agreement, granting investors certain registration rights for the shares and warrant shares.
Key Highlights
- Agreement dated April 3, 2026.
- Securities include common stock, pre-funded warrants, Tranche A-1 Common Warrants, and Tranche A-2 Common Warrants.
- Investors are granted registration rights for shares and warrant shares.
Price Impact
More from KPRX
More in Equity Offering
One & one Green Technologies Secures $13M in Follow-on Offering from Institutional Investors, with Option for Additional $3M
Linkers Industries Completes Full Exercise of Series B Cashless Warrants, Resulting in 1.52M Class A Shares Outstanding
Annovis Bio Secures $10M Public Offering, Extends Cash Runway to Q2 2027, Funds NDA Submission with AD Phase 3 Trial 75% Enrolled